What Could AI Mean for Patient Recruitment? Matthew Stumm Joins Panel Discussion at CTSS Boston 2026

As a Platinum Sponsor of the Clinical Trials Strategic Summit Boston 2026, Stark Raving Health is proud to announce that President and Founder Matthew Stumm will participate as a panelist in "AI at the Core: Reinventing Clinical Development from Molecule to Market, Including Trial Optimization and Patient Recruitment.

This April 22–23 in Boston, Matthew will join fellow industry leaders to examine how artificial intelligence is fundamentally reshaping the way clinical trials are designed, run, and how clinical study participants are found.

A Conversation That Meets This Moment

AI is no longer a peripheral tool in clinical research — it is at the early stages of becoming the connective tissue across the entire development lifecycle. From target identification and trial design to site selection, protocol optimization, and patient recruitment, the technology is creating new possibilities at every touchpoint.

Matthew's contribution to this conversation will be rooted in one of the most persistent challenges in clinical research: finding and enrolling the right patients.That's the work Stark Raving Health was built to do, and it's where the potential applications of AI are generating some of the most important discussions in the field today.

Bringing a Patient Recruitment Lens to the AI Conversation

Matthew comes to this conversation with a specific vantage point: the challenge of finding and engaging patients. Patient recruitment is where so many trials quietly struggle, and it’s also where some of the most pressing questions about AI’s potential role in clinical development are still being worked out.

How might AI reshape the media strategies that drive patient awareness and response? What could it mean for how sponsors reach people — across channels, across populations, across therapeutic areas — as these tools continue to evolve? And what are the right questions to be asking before organizations move further down that path?

These are the kinds of questions Matthew will bring to the panel. His perspective is rooted in years of hands-on patient recruitment work, and that experience shapes how he thinks about where AI could genuinely move the needle — and where caution and clarity are still needed. It’s an industry-wide conversation just getting started, and the summit feels like exactly the right place to have it.

Why Patient Recruitment Is at the Center of This Debate

The clinical trials community is at an inflection point. Decentralized trial models, shifting regulatory expectations, and growing pressure to serve more diverse patient populations have all intensified the stakes around enrollment. At the same time, AI tools are maturing rapidly — moving from proof-of-concept pilots to production-grade systems that sponsors and CROs may soon rely on.

The question is no longer whether AI belongs in clinical development. It’s how to deploy it well —thoughtfully, ethically, and in ways that actually move the needle on the metrics that matter. That’s the conversation Matthew is stepping into, and it’s one we believe the industry is ready to have.

Connect With Stark Raving Health at CTSS Boston

If you’re attending CTSS this April, we’d love to connect. Come find us at the Stark Raving Health booth, catch Matthew on the panel, or schedule a one-on-one conversation before or during the event. Whether you’re navigating enrollment challenges, exploring artificial intelligence, or simply want to compare notes on where the industry is headed —we’re here for that conversation.

And if you won’t be in Boston, stay tuned. We’ll be sharing key insights and takeaways from the summit right here, including highlights from the AI panel discussion.